JCM
SRNE

Jacobi Capital Management’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Jacobi Capital Management’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-6,660
Closed -$51K – 1424
2021
Q3 		$51K Hold
6,660
– – 0.01% 652
2021
Q2 		$65K Buy
6,660
+2,960
+80% +$23.6K 0.01% 569
2021
Q1 		$31K Buy
+3,700
New +$39.1K ﹤0.01% 696
2020
Q4 		– Sell
-5,000
Closed -$56K – 1397
2020
Q3 		$56K Buy
+5,000
New +$45.8K 0.01% 475

Other funds holding SRNE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Jacobi Capital Management's SRNE Position: Q4 2021 in Review

Jacobi Capital Management sold out of Sorrento Therapeutics, Inc. (SRNE) in Q4 2021, closing a stake of 6,660 shares — an estimated $51K sold.

Jacobi Capital Management first reported a position in SRNE in Q3 2020 and held it in 4 quarters. The position peaked at $65K in Q2 2021. 234 funds tracked by Wall St. Rank hold SRNE as of Q4 2021.

  • Jacobi Capital Management reported no remaining Sorrento Therapeutics, Inc. position as of Q4 2021 after selling out during the quarter.
  • Jacobi Capital Management sold 6,660 Sorrento Therapeutics, Inc. shares in Q4 2021, an estimated $51K.
  • Jacobi Capital Management first reported a position in Sorrento Therapeutics, Inc. in Q3 2020 and held it in 4 quarters.
  • Jacobi Capital Management's Sorrento Therapeutics, Inc. position peaked at $65K in Q2 2021.
  • 234 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q4 2021.

Based on Jacobi Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.